PearlDx specializes in the development and commercialization of diagnostic products aimed at the early detection and prevention of fungal infections. The company primarily serves patients who are at high risk of fungal infections, such as those undergoing organ transplantation, cancer therapy, or immunosuppressive treatments. Operating within the healthcare diagnostics market, PearlDx's business model focuses on creating and selling diagnostic tests that can identify fungal infections before they become severe, thereby improving patient outcomes and reducing healthcare costs. The company generates revenue through the sale of its diagnostic products, including its flagship urine test for detecting fungal infections in the lungs. PearlDx is based in the Johns Hopkins Fast Forward Accelerator in Baltimore, Maryland, and is a certified Women Owned Small Business by the U.S. Small Business Administration. The company has been active since 2014 and has received multiple patents for its innovative diagnostic technologies.

Keywords: fungal infections, early detection, diagnostic products, healthcare, immunocompromised patients, urine test, lung infections, commercialization, patents, Women Owned Small Business.